Comparison of the Effects of Growth Hormone and Insulin-like Growth Factor I on Substrate Oxidation and on Insulin Sensitivity in Growth Hormone-deficient Humans

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1994 Sep 1

PMID 8083353

Citations 16

Authors

M A Hussain

O Schmitz

A Mengel

Y Glatz

J S Christiansen

J Zapf

E R FROESCH

Affiliations

Soon will be listed here.

Abstract

Insulin-like growth factor-I (IGF-I) is considered to be the mediator of the growth-promoting effects of growth hormone (GH). The metabolic effects of these two hormones, however, are different. Whereas GH treatment leads to elevated insulin and glucose levels, reduced insulin sensitivity, and impaired glucose tolerance, IGF-I treatment leads to reduced insulin and GH levels and enhanced insulin sensitivity. IGF-I may, therefore, not only be the mediator of the growth-promoting effects of GH but also a modulator of the effects of GH on insulin action and glucose metabolism. To study the influence of GH and IGF-I on substrate metabolism and insulin sensitivity (assessed by euglycemic, hyperinsulinemic clamping combined with indirect calorimetry and glucose tracer infusion), we have treated eight GH-deficient adults with GH (2 IU/m2 daily subcutaneously [s.c.]), IGF-I (10 micrograms/kg.h s.c.), or both hormones together for 7 d, respectively, and compared the effects of these treatment regimens with a control phase. Our findings suggest that (a) both GH and IGF-I promote lipolysis and lipid oxidation, albeit by different mechanisms; (b) treatment with either hormone is followed by enhanced energy expenditure and reduced protein oxidation; and (c) IGF-I reverses the insulin resistance induced by GH.

Citing Articles

Insulin-like growth factor-1 levels are associated with high comorbidity of metabolic disorders in obese subjects; a Japanese single-center, retrospective-study.

Kubo H, Sawada S, Satoh M, Asai Y, Kodama S, Sato T Sci Rep. 2022; 12(1):20130.

PMID: 36418379 PMC: 9684525. DOI: 10.1038/s41598-022-23521-1.

Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.

Dichtel L, Cordoba-Chacon J, Kineman R J Clin Endocrinol Metab. 2022; 107(7):1812-1824.

PMID: 35172328 PMC: 9202731. DOI: 10.1210/clinem/dgac088.

Central Regulation of Metabolism by Growth Hormone.

Donato Jr J, Wasinski F, Furigo I, Metzger M, Frazao R Cells. 2021; 10(1).

PMID: 33440789 PMC: 7827386. DOI: 10.3390/cells10010129.

Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects.

Anderson L, Tamayose J, Garcia J Mol Cell Endocrinol. 2017; 464:65-74.

PMID: 28606865 PMC: 5723243. DOI: 10.1016/j.mce.2017.06.010.

A 90-day safety study of genetically modified rice expressing rhIGF-1 protein in C57BL/6J rats.

Tang M, Xie T, Cheng W, Qian L, Yang S, Yang D Transgenic Res. 2011; 21(3):499-510.

PMID: 21910016 DOI: 10.1007/s11248-011-9550-6.

References

Kupfer S, Underwood L, BAXTER R, Clemmons D . Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest. 1993; 91(2):391-6. PMC: 287936. DOI: 10.1172/JCI116212. View

Zenobi P, Graf S, Ursprung H, FROESCH E . Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest. 1992; 89(6):1908-13. PMC: 295890. DOI: 10.1172/JCI115796. View

Elahi D, Fukagawa N, Sclater A, Wong G, Shannon R, Minaker K . Effects of recombinant human IGF-I on glucose and leucine kinetics in men. Am J Physiol. 1993; 265(6 Pt 1):E831-8. DOI: 10.1152/ajpendo.1993.265.6.E831. View

SALMON Jr W, Daughaday W . A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957; 49(6):825-36. View

Poggi C, Le Marchand-Brustel Y, Zapf J, FROESCH E, Freychet P . Effects and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin. Endocrinology. 1979; 105(3):723-30. DOI: 10.1210/endo-105-3-723. View

Bar R, Harrison L, Muggeo M, Gorden P, Kahn C, Roth J . Regulation of insulin receptors in normal and abnormal physiology in humans. Adv Intern Med. 1979; 24:23-52. View

DEBODO R, Steele R, ALTSZULER N, Dunn A, Bishop J . ON THE HORMONAL REGULATION OF CARBOHYDRATE METABOLISM; STUDIES WITH C14 GLUCOSE. Recent Prog Horm Res. 1963; 19:445-88. View

DeFronzo R, Tobin J, Andres R . Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237(3):E214-23. DOI: 10.1152/ajpendo.1979.237.3.E214. View

Zapf J, Schoenle E, WALDVOGEL M, Sand I, FROESCH E . Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem. 1981; 113(3):605-9. DOI: 10.1111/j.1432-1033.1981.tb05105.x. View

10.

Berelowitz M, Szabo M, Frohman L, Firestone S, Chu L, Hintz R . Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science. 1981; 212(4500):1279-81. DOI: 10.1126/science.6262917. View

11.

DeFronzo R, Jacot E, Jequier E, MAEDER E, Wahren J, Felber J . The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 1981; 30(12):1000-7. DOI: 10.2337/diab.30.12.1000. View

12.

Smith D, DeFronzo R . The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab. 1982; 55(5):973-82. DOI: 10.1210/jcem-55-5-973. View

13.

Rizza R, Mandarino L, Gerich J . Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes. 1982; 31(8 Pt 1):663-9. DOI: 10.2337/diab.31.8.663. View

14.

Sherwin R, Schulman G, Hendler R, Walesky M, Belous A, Tamborlane W . Effect of growth hormone on oral glucose tolerance and circulating metabolic fuels in man. Diabetologia. 1983; 24(3):155-61. DOI: 10.1007/BF00250154. View

15.

Schwander J, Hauri C, Zapf J, FROESCH E . Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology. 1983; 113(1):297-305. DOI: 10.1210/endo-113-1-297. View

16.

DErcole A, Stiles A, Underwood L . Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A. 1984; 81(3):935-9. PMC: 344954. DOI: 10.1073/pnas.81.3.935. View

17.

Fukagawa N, Minaker K, Rowe J, Goodman M, Matthews D, Bier D . Insulin-mediated reduction of whole body protein breakdown. Dose-response effects on leucine metabolism in postabsorptive men. J Clin Invest. 1985; 76(6):2306-11. PMC: 424354. DOI: 10.1172/JCI112240. View

18.

Scheiwiller E, Guler H, Merryweather J, Scandella C, Maerki W, Zapf J . Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature. 1986; 323(6084):169-71. DOI: 10.1038/323169a0. View

19.

Ueda I, VAN DEN BRANDE J . Biosynthetic somatomedin C (SM-C/IGF-I) increases the length and weight of Snell dwarf mice. Pediatr Res. 1986; 20(9):825-7. DOI: 10.1203/00006450-198609000-00002. View

20.

KARLANDER S, Vranic M, Efendic S . Increased glucose turnover and glucose cycling in acromegalic patients with normal glucose tolerance. Diabetologia. 1986; 29(11):778-83. DOI: 10.1007/BF00873216. View